Substance / Medication

Ganirelix

SNOMED 395728002 UMLS C0073629

Overview

Active Ingredient

ganirelix

RxNorm CUI

35825

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Secondary Meig's syndrome

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

12 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study

NCT06175832Phase 4Recruiting60 enrolled

Efficacy of Micronized Natural Progesterone Vs GnRH Antagonist in the Prevention of LH Peak During Ovarian Stimulation.

NCT05954962Phase 4Recruiting150 enrolled

Disentangling the Effects of Daily Stress, Sleep, and Sex Hormones on Accelerated Vascular Aging in Midlife Women

NCT06745466Phase 4Recruiting30 enrolled

To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®

NCT03051087Phase 4Completed255 enrolled

Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation

NCT02069808Phase 4Completed38 enrolled

View all 12 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Efficacy and safety of newly developed ganirelix acetate in infertile women for assisted reproductive technology: a prospective, randomised, controlled study.

Han E Jung, Lyu Sang Woo, Kwak In Pyung et al. · J Obstet Gynaecol · 2022

PMID: 35254199RCT

Failure of the GnRH antagonist ganirelix to block the positive feedback effect of exogenous estrogen in normal women.

Messinis Ioannis E, Vanakara Polyxeni, Zavos Apostolos et al. · Fertil Steril · 2010

PMID: 20149361RCT

Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome.

Gustofson Robert L, Segars James H, Larsen Frederick W · Hum Reprod · 2006

PMID: 16966348RCT

A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.

DiLuigi Andrea J, Engmann Lawrence, Schmidt David W et al. · Fertil Steril · 2011

PMID: 21324455Observational

A comparison of pregnancy rates following fresh and frozen embryo transfer according to the use of leuprolide acetate vs ganirelix vs cetrorelix.

Check J H, Wilson C, Choe J K et al. · Clin Exp Obstet Gynecol · 2010

PMID: 21077496Observational

Ganirelix for luteolysis in poor responder patients undergoing IVF treatment: a Scandinavian multicenter 'extended pilot study'.

Nilsson Lars, Andersen Anders Nyboe, Lindenberg Svend et al. · Acta Obstet Gynecol Scand · 2010

PMID: 20504085Observational

A prospective comparison of in vitro fertilization (IVF) outcome following controlled ovarian hyperstimulation (COH) regimens using follitropin alpha exclusively or with the addition of low dose human chorionic gonadotropin (hCG) and ganirelix.

Check J H, Davies E, Brasile D et al. · Clin Exp Obstet Gynecol · 2009

PMID: 20101851Observational

Oral contraceptive pretreatment in women undergoing controlled ovarian stimulation in ganirelix acetate cycles may, for a subset of patients, be associated with low serum luteinizing hormone levels, reduced ovarian response to gonadotropins, and early pregnancy loss.

Meldrum David R, Scott Richard T, Levy Michael J et al. · Fertil Steril · 2009

PMID: 18339377Observational

The effect of cetrorelix vs. ganirelix on pregnancy outcome using minimal gonadotropin stimulation in women with elevated day 3 serum follicle stimulating hormone levels.

Check J H, Brasile D, Choe J K et al. · Clin Exp Obstet Gynecol · 2009

PMID: 19860353Observational

Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients.

Martínez Francisca, Clua Elisabet, Parera Nuria et al. · Gynecol Endocrinol · 2008

PMID: 18382904Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type: Substance / Medication
Fully Specified Name: Ganirelix (substance)
SNOMED CT: 395728002
UMLS CUI: C0073629
RxNorm CUI: 35825

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.